Compare EVER & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVER | BBNX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.6M | 493.1M |
| IPO Year | 2018 | N/A |
| Metric | EVER | BBNX |
|---|---|---|
| Price | $17.67 | $12.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $27.00 | $23.80 |
| AVG Volume (30 Days) | ★ 770.5K | 684.5K |
| Earning Date | 05-04-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 198.86 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $163,349,000.00 | N/A |
| Revenue This Year | $14.73 | $34.90 |
| Revenue Next Year | $11.51 | $34.63 |
| P/E Ratio | $35.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.88 | $8.80 |
| 52 Week High | $28.73 | $32.71 |
| Indicator | EVER | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 63.65 |
| Support Level | $17.25 | $9.34 |
| Resistance Level | $26.33 | $13.35 |
| Average True Range (ATR) | 1.06 | 0.76 |
| MACD | -0.14 | 0.30 |
| Stochastic Oscillator | 11.99 | 84.68 |
EverQuote Inc operates an online marketplace for insurance shopping, connecting consumers with insurance providers, including carriers and agents. Its marketplace is powered by proprietary data and technology platform that delivers high-intent, pre-validated consumer referrals aligned with insurers underwriting and profitability requirements. The platform provides transparency and campaign management tools, enabling providers to evaluate marketing spend performance and manage return on investment. Consumers can visit insurance provider websites, engage by phone, or submit data to receive quotes. Services are free for consumers, and the company derives revenue principally from consumer inquiries sold as referrals to insurance providers. It derives a majority of revenue from Direct channels.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.